Medicus Pharma Reports Expanded Phase 2 Skin Cancer Trial Data
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing a dose-response relationship for its SkinJect treatment candidate for nodular basal cell carcinoma, with the …
Medicus Pharma Reports Expanded Phase 2 Skin Cancer Trial Data Read More